Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
Rightangled is a healthcare technology company backed by NHS England & regulated by the Care Quality Commission (CQC). It began its journey as a platform that would enable the use of genetic information within the medical practice, in an accurate, streamlined, and affordable way. It gradually established itself as a healthcare provider for screening and diagnostic services. Its Heart DNA Test project, launched in 2017, is helping patients minimize their cardiac risks and enabling doctors to have a complete risk profile for their patients. The project was appreciated and received funding from NHS England. Its next project, Fitness DNA Test, tapped into the fitness and wellbeing markets. Recently, in the wake of the COVID-19 threat, the company has developed a home-based throat swab test to detect the viral infection, by testing viral load presented in its nucleic acid material within (RNA). For its efforts, Rightangled has been featured on CNN, Sky News, LBC radio, Sky News radio, and Newsweek. With the investment, the company aims to release a mobile application by the end of 2020, and develop an AI system to give instant tailored health, diet, and fitness advice to its users based on the data gathered from patient-doctor interactions and patient responses.
days to go:
Expired
investment:
£522,689
GP Nutrition is a nutrition company that creates products meant to deliver sustainable weight loss. This award-winning company was created by Gabriela Peacock, a celebrity nutritionist. It has 13,000 global customers who have bought more than 30,000 packs. In June'19, the company reached trading of £50k per month. It has produced 22 products that are now sold in 30 countries. GP Nutrition has delivered revenue of £377k and an EBITDA of £813,389. Nutrition's vision is to solve the 95% failure rate of diets in the USA and the UK.
days to go:
Expired
investment:
£309,890
The Ticket Bank (TTB) is an online ticketing marketplace that provides event tickets to disadvantaged and marginalised individuals free of charge. The company is powered by 'Tickets for Good'. It works with event organisers, charities, and community organisations to distribute otherwise unused event tickets to beneficiaries, creating unique life experiences that provide wide-ranging benefits to the health and wellbeing of its target audience. The platform already supports over 500+ charity partners who can choose tickets from over 50 venues/entertainment partners. The company introduced the 'Virtual Ticket Bank' and 'The Giving Back campaign' in the COVID-19 pandemic wherein it is sourcing thousands of tickets for National Health Service (NHS) and frontline care workers to express its gratitude for their services. They can use these tickets when the lockdown is over. The company will use the investment to create the integrations and data gathering tools to rapidly grow its channels, as well as, create additional value for both its charity and venue clients.
days to go:
Expired
investment:
£145,246
Run3D is a biotechnology company that has developed a 3D gait analysis system with the aim to help people identify injuries, deliver better performance, and make better running decisions. 3D gait analysis involves using infrared cameras to track positions of small reflective markers attached to a person in motion, capturing measurable data to help quantify a person's risk of injury, biomechanical efficiency, performance, footwear, and recommend proper diagnosis where necessary. The company plans to use the investment to grow its business.
days to go:
Expired
investment:
Withheld
Rebel Book Club is a developing subscription business of six hundred members who have read fifty-two books in four years. It delivers one non-fiction book every month and hosts a secret meetup featuring a book-inspired cocktail. The company has 600+ paying members in London, Bristol and Oxford, etc. and it receives 130+ average number of new applications monthly. The company hosts meetups at Entrepreneur First, Airbnb HQ, and WeWork. Rebel Book Club has collaborated with authors Matthew Syed (Rebel ideas), Kate Raworth (Doughnut Economics), Seth Godin (This is Marketing) and many more. The company aims to make the world's best non-fiction book club by growing a membership experience, build a reach code and support literacy projects.
days to go:
Expired
investment:
£148,070
One Year No Beer (OYNB) is a community support platform that helps people change their relationship with alcohol. It does this by allowing its users to choose a plan from the company's subscription-based models that consist of a 28-day, 90-day, and 365-day challenge to stay away from alcohol. The platform has empowered 70,000+ people in 90 countries through its challenges. Excess alcohol consumption leads to 3 million deaths per year and costs up to £59 billion to the UK economy alone. OYNB aims to resolve this crisis through its platform. For its efforts, the platform has been mentioned in publications such as the BBC, ITV, Metro, and Daily Telegraph. It also has an online presence of 130,000+ Facebook and 50,000+ Instagram followers. The company will use 42% of the investment to hire personnel, 33% for technology and product builds, and 25% as overhead costs.
days to go:
Expired
investment:
£1,757,111
